Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Peregrine looks to redefine bavituximab as immunotherapy

23:35 EDT 14 Jul 2013 | SCRIP

Tustin, California-based Peregrine is pressing forward with a Phase III clinical trial that pairs its phosphatidylserine (PS)-targeting monoclonal antibody with the chemotherapeutic agent docetaxel, but the company will continue a review of preclinic...

Original Article: Peregrine looks to redefine bavituximab as immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Peregrine looks to redefine bavituximab as immunotherapy"

Search BioPortfolio:
Advertisement

Relevant Topic

Antibodies
Latest News Clinical Trials Research Drugs Reports Corporate
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Advertisement

Searches Linking to this Story